FOVOCIP: A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia

Sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias (Other)

Overall Status

Recruiting

CT.gov ID

NCT05311254

Collaborator

Instituto de Investigación Marqués de Valdecilla (Other), Instituto de Salud Carlos III (Other)

156

Enrollment

Location

Arms

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Randomized phase 3 trial to compare efficacy and safety of oral fosfomycin versus ciprofloxacin to prevent febrile neutropenia in patients with acute leukemia or recipients of hematopoietic stem cell transplant.

Condition or Disease	Intervention/Treatment	Phase
Febrile Neutropenia	Drug: Fosfomycin Calcium	Phase 3

Detailed Description

Multicenter, prospective, randomized, open label phase III trial to assess the efficacy and safety of oral fosfomycin vs. oral ciprofloxacin in the prevention of febrile neutropenia in patients with acute leukemia who are treated with intensive chemotherapy and/or are recipients of a hematopoietic stem cell transplant.

Non-inferiority design.

156 patients will be recruited: 78 in each arm

Study Design

Study Type:

Interventional

Anticipated Enrollment :

156 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Multicenter, randomized, prospective, open-labelMulticenter, randomized, prospective, open-label

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

A Multicenter Randomized Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia in Hematological Patients: Efficacy and Microbiological Safety

Actual Study Start Date :

Mar 14, 2022

Anticipated Primary Completion Date :

Mar 14, 2023

Anticipated Study Completion Date :

Mar 14, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Fosfomycin Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.	Drug: Fosfomycin Calcium Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.
Active Comparator: Ciprofloxacin Oral ciprofloxacin, tablets containing 500 mg of active drug.	Drug: Fosfomycin Calcium Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.

Arm

Intervention/Treatment

Experimental: Fosfomycin

Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.

Drug: Fosfomycin Calcium

Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.

Active Comparator: Ciprofloxacin

Oral ciprofloxacin, tablets containing 500 mg of active drug.

Drug: Fosfomycin Calcium

Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count >0,5x109/L.

Outcome Measures

Primary Outcome Measures

Febrile neutropenia of infectious origin [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Febrile neutropenia that requires antibacterial treatment.

Secondary Outcome Measures

Documented infections [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Rate and type of documented infections
Use of broad spectrum antibiotics [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Index of days of antibiotics per hospitalization days. Antibiotics will be classified according the Watch/Reserve classification
Overall survival [Time from the day of randomization to the date of death, whatever the cause of death, up to 12 weeks.]
Drug related adverse events [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Incidence of Adverse Events (AE), severity and type of AEs.
Evolution of resistome [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Rate of patients colonized by multidrug resistant bacteria as determined by metagenomic sequencing
Microbiome evolution [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Changes in the gut microbiome produced under both prophylactic strategies during the study period.
Microbiological safety [Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum]
Rate of patients colonized by multidrug resistant bacteria as determined by surveillance cultures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure.
Adult subjects ≥ 18 years of age with acute leukemia diagnosis who are going to receive their first intensive chemotherapy cycle or adult subjects ≥ 18 years of age who are candidates to receive a first stem cell transplant.
Expected neutropenia 100x109/L lasting at least seven days. In case of expected neutropenia range 100-500x109/L lasting seven days or more, at least one of the following risk factors for infection must be present:
Performance status (Eastern Cooperative Oncology Group, ECOG) ≥2.
Expected mucositis grade 3-4.
Age ≥65 years.
Comorbidity Index (HCTI) ≥3.
Serum albumin< 35 g/L.
Total dose of etoposide > 500 mg/m2
Total dose of cytarabine > 1 g/m2
Active or refractory neoplasia at the moment of stem cell transplant.
Performance status (Eastern Cooperative Oncology Group, ECOG) of 0 to 3.
Adequate organ function defined as:

Liver: bilirubin, alkaline phosphatase, or SGOT < 3 times the upper normal limit (unless it is attributable to tumor activity).

Renal : creatinine ≤ 250 μmol/l (2.5 mg/dL) (unless it is attributable to AML activity).

Life expectancy higher than 3 months.
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.

Exclusion Criteria:

Hypersensitivity to fluoroquinolones or fosfomycin.
Treatment with broad spectrum antimicrobial therapy within 4 weeks of first study treatment.
Prior Intensive chemotherapy or stem cell transplant. Treatment with hydroxyurea or corticosteroids used to control white blood cell counts are permitted.
Fever of infectious origin or documented infection within 4 weeks of first study treatment.
Presence of any severe psychiatric disease or physical condition that, according to the physicians criteria, contraindicates the inclusion of the patient into the clinical trial.
Subjects that have participated previously in this study